The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 223.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.452%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 223.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

10 Mar 2020 07:00

RNS Number : 5158F
PureTech Health PLC
10 March 2020
 

10 March 2020

PureTech Health plc

 

Notice of Results

 

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

 

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at http://puretechhealth.com/investors under the Reports and Presentations tab.

 

PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

 

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBCGDXUXGDGGC
Date   Source Headline
1st Nov 202110:20 amRNSNew Research in Journal Nature on Gelesis Tech
1st Nov 20217:00 amRNSTotal Voting Rights
22nd Oct 20216:00 pmRNSHoldings in Company - TR-1 Correction Announcement
20th Oct 20214:35 pmRNSPrice Monitoring Extension
14th Oct 202112:01 pmRNSPRTC's Vedanta Appoints Chief Legal Officer
12th Oct 20217:00 amRNSAdditional Listing
5th Oct 20211:01 pmRNSVedanta Positive Phase 2 Data in C. Diff Infection
5th Oct 20211:00 pmRNSPRTC's Sonde Launches Mental Health Monitor
29th Sep 20211:01 pmRNSAkili/Shionogi Report Positive Ph2 Data in Japan
20th Sep 20214:02 pmRNSNew PureTech Research Published In Nature Journal
14th Sep 202112:00 pmRNSPRTC to Present at Oppenheimer Healthcare Summit
1st Sep 20217:00 amRNSTotal Voting Rights
24th Aug 20217:00 amRNSHalf-year Report
23rd Aug 202112:00 pmRNSPRTC Presents LYT-100 Ph1 PK & Tolerability at ERS
17th Aug 20211:03 pmRNSAkili Deal Furthers Digital Medicine Leadership
13th Aug 202112:00 pmRNSPRTC Appoints Industry Veteran & Physician as CMO
11th Aug 202112:00 pmRNSPRTC Receives $6.5M; Imbrium to Develop LYT-503
3rd Aug 20217:00 amRNSNotice of Results
2nd Aug 20217:00 amRNSTotal Voting Rights
23rd Jul 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
22nd Jul 20211:03 pmRNSPRTC’s Akili Releases New Features for EndeavorRx
22nd Jul 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
21st Jul 202112:03 pmRNSPureTech’s Vedanta Raises $68M Series D Financing
19th Jul 202112:02 pmRNSPRTC’s Gelesis to Become Public Via Capstar SPAC
9th Jul 202112:00 pmRNSPRTC’s Vor Announces Collaboration with Janssen
8th Jul 20212:05 pmRNSPRTC’s Sonde Announces Collaboration With Qualcomm
7th Jul 202112:00 pmRNSPRTC BeiGene LYT-200 Clinical Trial Agreement
1st Jul 20217:00 amRNSTotal Voting Rights
30th Jun 202112:00 pmRNSPRTC’s Vedanta Announces New Data from IBD Study
28th Jun 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Jun 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Jun 20211:28 pmRNSKaruna Announces KarXT Results in Healthy Elderly
16th Jun 202112:00 pmRNSPureTech Acquires Alivio and Oral IL-22 Candidate
2nd Jun 20217:00 amRNSPDMR Notification RSU Vesting
1st Jun 20217:00 amRNSTotal Voting Rights
27th May 20216:16 pmRNSResult of AGM
27th May 20212:50 pmRNSPureTech’s Gelesis Presents Plenity Data at AACE
26th May 20211:05 pmRNSPureTech’s Akili Secures $160M in Financing
25th May 202112:00 pmRNSPRTC Presents at Jefferies Healthcare Conference
12th May 202112:00 pmRNSPureTech Forms IPF Clinical Advisory Board
28th Apr 20214:08 pmRNSNew PureTech Research Published in Nature Journal
26th Apr 20211:05 pmRNSGelesis Appoints Procter & Gamble Veteran to BOD
15th Apr 20217:00 amRNSFinal Results
12th Apr 202112:00 pmRNSPRTC Presents Data for LYT-210 IO Program at AACR
7th Apr 202112:00 pmRNSPureTech to Present at Two Investor Conferences
7th Apr 202110:15 amRNSAkili Collab to Study Long COVID-Related Brain Fog
26th Mar 202112:02 pmRNSAkili Data Published in Nature Digital Medicine
24th Mar 20217:00 amRNSHolding(s) in Company
18th Mar 20217:00 amRNSDirectorate Change
15th Mar 20217:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.